Fluoroquinolones and isoniazid resistant TB: implications for the 2018 WHO guidance

HR Stagg, GH Bothamley, JA Davidson, H Kunst, MK Lalor, MC Lipman, MG Loutet, S Lozewicz, T Mohiyuddin, A Abbara, E Alexander, H Booth, DD Creer, RJ Harris, OM Kon, MR Loebinger, TD McHugh, HJ Milburn, P Palchaudhuri, PPJ PhillipsE Schmok, L Taylor, I Abubakar, on behalf of the London INH-R TB study group

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION: 2018 World Health Organization (WHO) guidelines for the treatment of isoniazid (H) resistant (Hr) tuberculosis recommend a four-drug regimen- rifampicin (R), ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx)- with or without H ([H]RZE-Lfx). This is used once Hr is known, such that patients complete 6 months of Lfx (≥6[H]RZE-6Lfx). This cohort study assessed the impact of fluoroquinolones (Fq) on treatment effectiveness, accounting for Hr mutations and degree of phenotypic resistance.

METHODS: This was a retrospective cohort study of 626 Hr tuberculosis patients notified in London, 2009-2013. Regimens were described and logistic regression undertaken of the association between regimen and negative regimen-specific outcomes (broadly, death due to tuberculosis, treatment failure, disease recurrence).

RESULTS: Of 594 individuals with regimen information, 330 (55.6%) were treated with (H)RfZE (Rf=rifamycins) and 211 (35.5%) with (H)RfZE-Fq. The median overall treatment period was 11.9 months and median Z duration 2.1 months. In a univariable logistic regression model comparing (H)RfZE with and without Fqs, there was no difference in the odds of a negative regimen-specific outcome (baseline (H)RfZE, cluster-specific odds ratio 1.05 [95% confidence interval 0.60-1.82], p-value 0.87; cluster NHS Trust). Results varied minimally in a multivariable model. This odds ratio dropped (0.57 [0.14-2.28]) when Hr genotype was included, but this analysis lacked power (p=0.42).

CONCLUSIONS: In a high-income setting, we found a 12 month (H)RfZE regimen with a short Z duration to be similarly effective for Hr TB with or without a Fq. This regimen may result in fewer adverse events than the WHO recommendations.
Original languageEnglish
JournalEuropean Respiratory Journal
DOIs
Publication statusPublished - 10 Oct 2019

Fingerprint

Dive into the research topics of 'Fluoroquinolones and isoniazid resistant TB: implications for the 2018 WHO guidance'. Together they form a unique fingerprint.

Cite this